Literature DB >> 2995829

Amplification and altered expression of the c-myc oncogene in A-MuLV-transformed fibroblasts.

A Nepveu, P D Fahrlander, J Q Yang, K B Marcu.   

Abstract

Chromosomal rearrangements involving the c-myc oncogene are a prevalent feature of plasmacytomas that arise after inoculating BALB/c mice with pristane and Abelson murine leukaemia virus (A-MuLV). With this observation in mind, we decided to determine if any genetic alterations of the c-myc locus could be observed in cells of a different type, when transformed in vitro by A-MuLV. Here we have analysed three independent A-MuLV-transformed NIH 3T3 lines (ANN-I, 54c12 and N25), and found that the c-myc locus is amplified 8-19-fold in each transformant. Quantitative S1 nuclease mapping performed on ANN-I and 54c12 RNAs demonstrated that: (1) c-myc messenger RNAs accumulated to double the levels found in NIH 3T3 cells; and (2) a shift in the use of the two normal c-myc transcription initiation sites (P1 and P2) occurred in favour of the 3' site, P2. Analysis of c-myc chromatin by DNase I treatment of 54c12 nuclei revealed that most, if not all, of the c-myc gene copies were transcriptionally competent. We present alternative ideas to explain why amplification of the c-myc gene occurs repeatedly in A-MuLV-transformed fibroblasts. Finally, we discuss our results in relation to the hypothesis linking the phenomenon of tumour progression with the amplification of oncogenes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995829     DOI: 10.1038/317440a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  11 in total

1.  A cis-acting element in the promoter region of the murine c-myc gene is necessary for transcriptional block.

Authors:  H Miller; C Asselin; D Dufort; J Q Yang; K Gupta; K B Marcu; A Nepveu
Journal:  Mol Cell Biol       Date:  1989-12       Impact factor: 4.272

2.  Frequent amplification of c-myc in ground squirrel liver tumors associated with past or ongoing infection with a hepadnavirus.

Authors:  C Transy; G Fourel; W S Robinson; P Tiollais; P L Marion; M A Buendia
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

3.  bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation.

Authors:  A Engelman; N Rosenberg
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

4.  Expression of c-myc proto-oncogene in normal human lymphocytes. Regulation by transcriptional and posttranscriptional mechanisms.

Authors:  J C Reed; J D Alpers; P C Nowell
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

5.  Synergism of v-myc and v-Ha-ras in the in vitro neoplastic progression of murine lymphoid cells.

Authors:  R C Schwartz; L W Stanton; S C Riley; K B Marcu; O N Witte
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

6.  An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene.

Authors:  H Rosenbaum; A W Harris; M L Bath; J McNeall; E Webb; J M Adams; S Cory
Journal:  EMBO J       Date:  1990-03       Impact factor: 11.598

7.  The first exon of the c-myc proto-oncogene contains a novel positive control element.

Authors:  J Q Yang; E F Remmers; K B Marcu
Journal:  EMBO J       Date:  1986-12-20       Impact factor: 11.598

8.  Chromosome 8 breakpoint far 3' of the c-myc oncogene in a Burkitt's lymphoma 2;8 variant translocation is equivalent to the murine pvt-1 locus.

Authors:  M Graham; J M Adams
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

9.  Amplification and overexpression of the met gene in spontaneously transformed NIH3T3 mouse fibroblasts.

Authors:  C S Cooper; P R Tempest; M P Beckman; C H Heldin; P Brookes
Journal:  EMBO J       Date:  1986-10       Impact factor: 11.598

10.  Oncogenic v-Abl tyrosine kinase can inhibit or stimulate growth, depending on the cell context.

Authors:  M W Renshaw; E T Kipreos; M R Albrecht; J Y Wang
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.